Purple Biotech (XTAE:PPBT) Total Liabilities : ₪14.64 Mil (As of Dec. 2024)

View and export this data going back to 1978. Start your Free Trial

What is Purple Biotech Total Liabilities?

Purple Biotech's Total Liabilities for the quarter that ended in Dec. 2024 was ₪14.64 Mil.

Purple Biotech's quarterly Total Liabilities declined from Jun. 2024 (₪23.72 Mil) to Sep. 2024 (₪19.99 Mil) and declined from Sep. 2024 (₪19.99 Mil) to Dec. 2024 (₪14.64 Mil).

Purple Biotech's annual Total Liabilities increased from Dec. 2022 (₪26.68 Mil) to Dec. 2023 (₪35.48 Mil) but then declined from Dec. 2023 (₪35.48 Mil) to Dec. 2024 (₪14.64 Mil).

Purple Biotech Total Liabilities Historical Data

The historical data trend for Purple Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Total Liabilities Chart

Purple Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

14.37

18.06

26.68

35.48

14.64

Purple Biotech Quarterly Data
	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															35.48	31.11	23.72	19.99	14.64

Purple Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Purple Biotech's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.139	+	(0	+	4.4408920985006E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0.496	+	0)
	=	14.64

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	131.346	-	116.711
	=	14.64

Purple Biotech's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.139	+	(0	+	4.4408920985006E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0.496	+	0)
	=	14.64

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	131.346	-	116.711
	=	14.64

Purple Biotech Total Liabilities Related Terms

Thank you for viewing the detailed overview of Purple Biotech's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Purple Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (XTAE:PPBT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

PPBT:USA

Address

4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104

Website

https://www.purple-biotech.com

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.